[Propause survey: profile of patients treated with progestins in perimenopause]

Patrice Lopès, P Lopès, B Schatz
Journal de gynecologie, obstetrique et biologie de la reproduction · 2005 · vol. 34(3) , pp. 232–240 · doi:10.1016/s0368-2315(05)82741-3 · PMID:16012383 · W1997891180
Observational OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-02 ⓘ

A 1998 French survey of 284 gynecologists revealed that progestin prescriptions for perimenopause frequently deviated from recommended usage patterns, with indications including endometrial pathology and treatment durations varying significantly by clinical presentation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

UNLABELLED: Progestins are widely used in France for treatment of perimenopause. OBJECTIVES: To evaluate the real use of progestins in daily practice. MATERIAL AND METHODS: A transverse epidemiological survey conducted between May and June 1998, by 284 gynecologists representative of French private practitioner gynecologists, who selected the first 4 patients treated with progestins for perimenopause. RESULTS: For 887 observations collected, the most frequent indications of prescription were: functional disorders of perimenopause (57%), mastalgia (47%), premenstruel syndrome (38%), endometrial pathology (29%) and ovulation inhibition (28%). Multiple reasons were present in 81% of patients: when progestin was prescribed more than 10 days per cycle, breast pathologies were the most frequent indication and the length of treatment was more than one year; when progestin was prescribed 10 days per cycle, isolated menstrual irregularities (without breast or endometrium pathology) predominated and the length of treatment was one year or less. The most widely used progestin classes were pregnanes and norpregnanes; there was an estrogene co-prescription in 17% of cases, more frequently in women with perimenopause disorders. CONCLUSION: We found the following pattern for progestin prescription in perimenopause: 10-day prescription for one-third of the women, 11 to 15 days for one-third, and 20 days per cycle for one-third. We thus observe some differences with recommended use. This difference is observed either with the initial prescription or with symptom-related dose adaptation.

My notes (saved in your browser only)

MeSH descriptors

Perimenopause Progestins Drug Prescriptions Drug Prescriptions Female France Gynecology Humans Practice Patterns, Physicians' Private Practice Progestins Progestins Time Factors

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (19)

Source provenance

openalex
last seen: 2026-05-11T06:01:13.017405+00:00
pubmed
last seen: 2026-10-08T21:03:18.265172+00:00
unpaywall
last seen: 2026-10-19T06:34:38.229974+00:00
License: CC0 · commercial use OK